Denali Therapeutics Inc. (NASDAQ:DNLI) Holdings Boosted by Yiheng Capital Management L.P.

Yiheng Capital Management L.P. lifted its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 16.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 700,098 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Denali Therapeutics comprises 0.5% of Yiheng Capital Management L.P.’s portfolio, making the stock its 11th largest position. Yiheng Capital Management L.P. owned approximately 0.49% of Denali Therapeutics worth $14,268,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Victory Capital Management Inc. grew its stake in Denali Therapeutics by 163.7% during the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after buying an additional 24,767 shares during the last quarter. FMR LLC increased its holdings in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after acquiring an additional 7,596,508 shares during the period. Algert Global LLC lifted its position in Denali Therapeutics by 82.4% in the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock valued at $1,417,000 after purchasing an additional 21,975 shares during the last quarter. Proficio Capital Partners LLC acquired a new position in Denali Therapeutics during the 4th quarter valued at about $514,000. Finally, JPMorgan Chase & Co. grew its position in Denali Therapeutics by 6.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after purchasing an additional 14,324 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the completion of the transaction, the insider now owns 178,580 shares in the company, valued at approximately $3,610,887.60. This represents a 6.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,940 shares of company stock valued at $973,442. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Stock Down 1.4 %

Shares of Denali Therapeutics stock opened at $14.61 on Friday. Denali Therapeutics Inc. has a 12-month low of $14.01 and a 12-month high of $33.33. The firm has a market capitalization of $2.12 billion, a PE ratio of -5.29 and a beta of 1.46. The stock’s fifty day moving average is $19.78 and its 200-day moving average is $23.70.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08. Analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DNLI. Morgan Stanley began coverage on Denali Therapeutics in a report on Friday, March 7th. They set an “overweight” rating and a $33.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Bank of America decreased their price target on Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, March 10th. HC Wainwright lifted their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 target price for the company. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.20.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.